Jennifer Bordeaux
Overview
Explore the profile of Jennifer Bordeaux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shiuan E, Reddy A, Dudzinski S, Lim A, Sugiura A, Hongo R, et al.
Cancers (Basel)
. 2021 Apr;
13(6.
PMID: 33806963
Predicting response to ICI therapy among patients with renal cell carcinoma (RCC) has been uniquely challenging. We analyzed patient characteristics and clinical correlates from a retrospective single-site cohort of advanced...
2.
Najjar Y, McCurry D, Lin H, Lin Y, Zang Y, Davar D, et al.
Clin Cancer Res
. 2021 Mar;
27(15):4195-4204.
PMID: 33753453
Purpose: Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b...
3.
Franklin D, Sharick J, Ericsson-Gonzalez P, Sanchez V, Dean P, Opalenik S, et al.
JCI Insight
. 2020 Jul;
5(15).
PMID: 32634121
Triple-negative breast cancers (TNBCs) are heterogeneous and aggressive, with high mortality rates. TNBCs frequently respond to chemotherapy, yet many patients develop chemoresistance. The molecular basis and roles for tumor cell-stromal...
4.
Iams W, Shiuan E, Meador C, Roth M, Bordeaux J, Vaupel C, et al.
J Thorac Oncol
. 2019 Jun;
14(11):1970-1981.
PMID: 31201935
Background: Approximately 10% of patients with SCLC develop a paraneoplastic syndrome (PNS). Neurologic PNS are thought to improve prognosis, which we hypothesized is related to increased tumor-infiltrating lymphocytes and immune...
5.
Johnson D, Nixon M, Wang Y, Wang D, Castellanos E, Estrada M, et al.
JCI Insight
. 2018 Dec;
3(24).
PMID: 30568030
Immunotherapies targeting the PD-1 pathway produce durable responses in many cancers, but the tumor-intrinsic factors governing response and resistance are largely unknown. MHC-II expression on tumor cells can predict response...
6.
Johnson D, Bordeaux J, Kim J, Vaupel C, Rimm D, Ho T, et al.
Clin Cancer Res
. 2018 Jul;
24(21):5250-5260.
PMID: 30021908
PD-1/L1 axis-directed therapies produce clinical responses in a subset of patients; therefore, biomarkers of response are needed. We hypothesized that quantifying key immunosuppression mechanisms within the tumor microenvironment by multiparameter...
7.
Siska P, Johnpulle R, Zhou A, Bordeaux J, Kim J, Dabbas B, et al.
Oncoimmunology
. 2017 May;
6(4):e1305535.
PMID: 28507813
Platinum-based chemotherapy is usually curative for patients with testicular germ cell tumors (TGCT), but a subset of patients experience disease progression and poor clinical outcomes. Here, we tested whether immune...
8.
Beckermann K, Jolly P, Kim J, Bordeaux J, Puzanov I, Rathmell W, et al.
J Immunother Cancer
. 2017 Jan;
5:1.
PMID: 28105368
Background: Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent...
9.
OShannessy D, Somers E, Chandrasekaran L, Nicolaides N, Bordeaux J, Gustavson M
Oncotarget
. 2014 Jul;
5(12):3983-95.
PMID: 24980818
Tumor survival is influenced by interactions between tumor cells and the stromal microenvironment. One example is Endosialin (Tumor Endothelial Marker-1 (TEM-1) or CD248), which is expressed primarily by cells of...
10.
Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister V, et al.
PLoS One
. 2014 Jun;
9(6):e99131.
PMID: 24968015
Background: We sought to determine the predictive value of in situ mRNA measurement compared to traditional methods on a cohort of trastuzumab-treated metastatic breast cancer patients. Methods: A tissue microarray...